Clinical trials: Carcinoids
Neuroendocrine Tumors, Carcinoid Syndrome
A Study to Assess Neuroendocrine Tumour (NET) Patients Currently Treated by Somatuline Autogel for History of Carcinoid Syndrome Associated With Episodes of Diarrhea
The purpose of the protocol is to to assess subject's overall satisfaction regarding control of diarrhea. The study aims to supplement results obtained through clinical trials with data obtained from a population of patients…
- Trial name
- SYMNET (NCT01234168)
- Where
- 57 sites in Czechia, France and 6 more
- Volunteers
- 340 people
- Sponsor
- Ipsen
Malignant Carcinoid Syndrome
Comparison of Lanreotide Autogel® and Sandostatin LAR Depot in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome
The aim of this study is to compare the efficacy and safety of lanreotide Autogel and Sandostatin LAR Depot, to see whether these two 28-day prolonged release formulations produce a similar clinical response in patients with…
- Trial name
- NCT00092287
- Testing
- lanreotide Autogel (somatostatin analogue), Sandostatin long acting release (LAR) Depot (somatostatin analogue)
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Ipsen
Neuroendocrine Tumour With Carcinoid Symptoms
Somatuline Autogel Preference and Health Economy Study
The primary aim of this study is to assess which method of lanreotide Autogel administration patients with neuroendocrine tumours prefer - self/partner administrations or healthcare provided administrations.
- Trial name
- SAPHE (NCT00681187)
- Testing
- lanreotide (Autogel formulation)
- Where
- 10 sites in Denmark, Norway and 1 more
- Volunteers
- 26 people
- Sponsor
- Ipsen
Carcinoma, Neuroendocrine Tumors
A Study of Cixutumumab (IMC-A12) in Islet Cell Cancer
Determine the 6-month progression free survival (PFS) rate associated with cixutumumab in combination with depot octreotide acetate (octreotide) in participants with metastatic neuroendocrine tumors.
- Trial name
- NCT00781911
- Testing
- Cixutumumab, depot octreotide
- Where
- 10 sites in United States
- Volunteers
- 43 people
- Sponsor
- Eli Lilly and Company
Carcinoid Syndrome
Telotristat Etiprate - Expanded Treatment for Patients With Carcinoid Syndrome Symptoms
The primary objective of this study is to evaluate the long-term safety and tolerability of orally administered telotristat etiprate.
- Trial name
- TELEPATH (NCT02026063)
- Testing
- Telotristat etiprate
- Where
- 43 sites in United States, Australia and 10 more
- Volunteers
- 124 people
- Sponsor
- Lexicon Pharmaceuticals
Chronic Atrophic Gastritis, Hypergastrinaemia
YF476 and Type I Gastric Carcinoids
The aim of the study is to find out if the experimental medicine, YF476, can make gastric carcinoids, a rare type of stomach tumour, shrink and disappear.
- Conditions
- Chronic Atrophic Gastritis, Hypergastrinaemia, Type I Gastric Carcinoids
- Trial name
- NCT01339169
- Testing
- YF476
- Where
- United Kingdom
- Volunteers
- 8 people
- Sponsor
- Trio Medicines Ltd.
Carcinoid Syndrome
Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome
The purpose of the study is to evaluate the safety and tolerability of orally administered telotristat etiprate (LX1606) in participants with symptomatic carcinoid syndrome.
- Trial name
- NCT01104415
- Testing
- Telotristat etiprate
- Where
- 10 sites in Germany, United Kingdom
- Volunteers
- 15 people
- Sponsor
- Lexicon Pharmaceuticals
Advanced and Metastatic Silent Neuro-Endocrine Tumors, Carcinoma
RAMSETE: RAD001 in Advanced and Metastatic Silent Neuro-endocrine Tumors in Europe
To evaluate the preliminary efficacy and safety of RAD001 as monotherapy for first-line treatment of patients with metastatic papillary carcinoma of the kidney.
- Conditions
- Advanced and Metastatic Silent Neuro-Endocrine Tumors, Carcinoma, Neuroendocrine, Non Functioning Neuroendocrine Tumors (NETs)
- Trial name
- RAMSETE/CDE16 (NCT00688623)
- Testing
- Everolimus
- Where
- 40 sites in France, Germany and 6 more
- Volunteers
- 73 people
- Sponsor
- Novartis Pharmaceuticals
Cancer, Neuroendocrine Tumors
A Dose Finding Study of TKM-080301 Infusion in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients
This study will be a Phase I/II, open-label, non-randomized, dose-finding trial conducted at multiple clinical centers. The study is designed to determine the safety, tolerability and PK of TKM-080301 in adult patients with solid…
- Conditions
- Cancer, Neuroendocrine Tumors, NET, Adrenocortical Carcinoma
- Trial name
- NCT01262235
- Testing
- TKM-080301
- Where
- 8 sites in United States
- Volunteers
- 68 people
- Sponsor
- Arbutus Biopharma Corporation
Carcinoid Syndrome
Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome Not Managed by Stable-Dose Octreotide Therapy
The purpose of this study is to evaluate the safety and tolerability of telotristat etiprate (LX1606) versus a placebo control in participants with symptomatic carcinoid syndrome not managed by stable-dose long-acting octreotide…
- Trial name
- NCT00853047
- Testing
- Telotristat etiprate, Octreotide LAR Depot
- Where
- 9 sites in United States
- Volunteers
- 23 people
- Sponsor
- Lexicon Pharmaceuticals
Carcinoid Syndrome
TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome)
The primary objective of the study is to confirm that at least 1 or more doses of telotristat etiprate compared to placebo is effective in reducing the number of daily bowel movements (BMs) from baseline averaged over the 12-week…
- Trial name
- NCT01677910
- Testing
- Telotristat etiprate
- Where
- 75 sites in United States, Australia and 10 more
- Volunteers
- 135 people
- Sponsor
- Lexicon Pharmaceuticals
Carcinoid Syndrome
Telotristat Etiprate for Carcinoid Syndrome Therapy
The purpose of the study is to evaluate the effect of telotristat etiprate versus placebo on the incidence of treatment-emergent adverse events and on 5-hydroxyindoleacetic acid (5-HIAA) levels.
- Trial name
- TELECAST (NCT02063659)
- Testing
- Telotristat etiprate
- Where
- 50 sites in United States, Australia and 9 more
- Volunteers
- 76 people
- Sponsor
- Lexicon Pharmaceuticals
Neuroendocrine Tumors
A Ph 2 Study of Fosbretabulin in Subjects w Pancreatic or Gastrointestinal Neuroendocrine Tumors w Elevated Biomarkers
This study will investigate the safety, symptoms and biomarker response of subjects with biopsy-proven well-differentiated, low-to-intermediate-grade, unresectable, or metastatic pancreatic neuroendocrine tumors (PNETs) or or…
- Trial name
- GI-NETorPNET (NCT02132468)
- Testing
- fosbretabulin tromethamine
- Where
- 5 sites in United States
- Volunteers
- 18 people
- Sponsor
- Mateon Therapeutics
Carcinoid, Neuroendocrine Tumors
EPO906 in Carcinoid and Other Neuroendocrine Tumors
This study will examine whether the new investigational drug EPO906, given by intravenous infusion (IV directly into the vein), is effective in shrinking tumors and preventing the growth of cells that cause metastatic carcinoid…
- Trial name
- NCT00050349
- Testing
- EPO906 epothilone B
- Where
- 5 sites in United States
- Volunteers
- 33 people
- Sponsor
- Novartis Pharmaceuticals
Malignant Carcinoid Tumor
Study to Evaluate the Efficacy and Safety of 90Y-SMT487 in Subjects With Symptomatic Malignant Carcinoid Tumors
Subjects will be screened to determine OctreoScan® uptake. And upon meeting the eligibility criteria, 90 subjects will complete a symptom assessment scale at baseline and throughout the study at specific time points.
- Trial name
- NCT00696930
- Testing
- 90Y-SMT487
- Sponsor
- Molecular Insight Pharmaceuticals, Inc.
Chronic Atrophic Gastritis, Hypergastrinemia
YF476 and Type I Gastric Carcinoids (Norway)
The aim of the study is to find out if the experimental medicine, YF476, can make gastric carcinoids, a rare type of stomach tumour, shrink and disappear.
- Conditions
- Chronic Atrophic Gastritis, Hypergastrinemia, Type I Gastric Carcinoids
- Trial name
- NCT01444014
- Testing
- YF476
- Where
- Norway
- Volunteers
- 8 people
- Sponsor
- Trio Medicines Ltd.
Carcinoid Tumor, Malignant Carcinoid Syndrome
Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor
The purpose of this study was to evaluate whether everolimus 10 mg / day added to treatment with depot octreotide prolongs progression free survival compared to treatment with octreotide alone in patients with advanced carcinoid…
- Trial name
- RADIANT-2 (NCT00412061)
- Testing
- Octreotide, Everolimus
- Where
- 70 sites in United States, Australia and 13 more
- Volunteers
- 429 people
- Sponsor
- Novartis Pharmaceuticals
Carcinoid Syndrome
An Open-label Study to Evaluate the Absorption, Metabolism, and Excretion of [14C]-Telotristat Etiprate in Males
To evaluate the metabolism and routes and extent of elimination of telotristat etiprate and its primary metabolite LX1033.
- Trial name
- LX1606-104 (NCT01932528)
- Testing
- 500 mg [14C]-LX1606
- Where
- United Kingdom
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Lexicon Pharmaceuticals
Carcinoid Syndrome
Pharmacokinetics, Efficacy and Safety of an Octreotide Implant in Patients With Carcinoid Syndrome
Evaluate the pharmacokinetics, safety and efficacy of an octreotide implant for the treatment of the symptoms of carcinoid syndrome.
- Trial name
- NCT00884715
- Testing
- Octreotide
- Where
- 3 sites in United States
- Volunteers
- 10 people
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
Symptomatic Refractory Resistant Carcinoid Disease
Efficacy and Safety of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients With Metastatic Carcinoid Disease
The purpose of this randomized, multicenter, Phase III study was to compare the efficacy of paseriotide LAR and octreotide LAR in patients whose disease-related symptoms are inadequately controlled by currently available…
- Trial name
- NCT00690430
- Testing
- Pasireotide, Octreotide
- Where
- 62 sites in United States, Argentina and 14 more
- Volunteers
- 186 people
- Sponsor
- Novartis Pharmaceuticals